References
- Price RK, North CS, Nessely S, Fraser, VJ: Estimating the prevalence of chronic fatigue syndrome in the community. Public Health Reports 107: 514–22, Sept-Oct 1992.
- Marchesani RB: Critical antiviral pathway deficient in CFS patients. Infec-tious Disease News 4, August 1993.
- Goldenberg DL: Fibromyalgia syndrome. JAMA 257: 2782–87, 1987.
- Jefferies W: Safe Uses of Cortisone. Charles C. Thomas [Publisher], Springfield, 1981.
- Jefferies W: Low dose glucocorticoid therapy. Archives of Internal Medi-cine 119: 265–78, 1967.
- Rosenbaum M, Susser M: Solving the Puzzle of Chronic Fatigue Syn-drome. Life Sciences Press, Tacoma, 1992.
- Medical Letter: 34: 14, Feb 1992.
- Sternberg EM: Hypoimmune fatigue syndromes—Diseases of the stress re-sponse. [Editorial] J Rheumatol 20: 418–21, 1993.
- Neeck G, Riedel W: Thyroid function in patients with fibromyalgia syn-drome. J Rheumatol 19: 1120–22, 1992.
- Demitrack MA, Dale RC, Strauss SE, Laue L, Listwak SJ, Kruesi, MJ: Evi-dence for impaired activation of the hypothalamic-pituitary-adrenal axis in pa-tients with chronic fatigue syndrome. J Clin Endo Metab 73: 1224–34, 1991.
- Bakheit Amo, Behan PO, Dinan TG, Gray, CE, O'Keane V: Possible upre-gulation of hypothalamic 5HT receptors in patients with postviral fatigue syn-drome. BMJ 304: 1010–12, April 1992.
- Griep EN, Boersma JW, deKlset ER: Altered reactivity of the HPA axis in the primary fibromyalgia syndrome. J Rheumatol 20: 469–474, 1993.
- McCain GA, Tilbe KS: Diurnal hormone variation in fibromyalgia syn-drome: A comparison with Rheumatoid Arthritis. J Rheumatol 25: 469–474, 1993.
- Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU: Clinical toxic-ity of interferons in cancer patients: A review. J Clin Oncology 4: 234–43, Feb 1986.
- Adams F, Quesada JR, Gutterman JU: Neuropsychiatric manifestations of human leucocyte interferon therapy in patients with cancer. JAMA 252: 938–941, 1984.
- Meikle AW, Daynes RA, Araneo BA, Parker LN: Adrenal androgen secre-tion and biologic effects and control of adrenal androgen secretion. Endocrine and Metab. Clinics of North America 20, #2: 381–421, June 1991.
- Travell JG, Simons DG: Myofascial Pain & Dysfunction; The Trigger Point Manual. Williams & Wilkins, Baltimore, 1983, pp. 103–64.
- Lindenbaum J, Healton ER, Savage DG, Brust JCM, Garrett TJ, Podell ER: Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. NEJM 318: 1720–28, 1988.
- Carmel R: Pernicious Anemia—The expected findings of very low serum cobalamin levels, anemia and macrocytosis are often lacking. Arch Intern Med 148: 1712–14, 1988.
- Norman EJ, Morrison JA: Screening for Vitamin B12 deficiency using uri-nary MMA. Am J Med 94: 589–94, June 1993.
- Lindenbaum J, Rosenberg Ill, Wilson PWF, Stabler SP, Allen RH: Preva-lence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 60: 2–11, 1994.
- Strauss SE, Fritz S, Dale JK, Gould B, Strober W: Lymphocyte phenotype and function in CFS. J Clin Immunol 13: 30–40, Jan 1993.